21 November 2017
News and Views
Links and Services
A study in the latest issue of Inflammatory Bowel Diseases compares adalimumab with traditional non-biological therapies for Crohn's disease.
Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD).
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors